Search clinical trials for: IR (Immediate-Release) quetiapine fumarate (drug)

Total 1049 results

AstraZeneca

Completed

Rapid Dose Escalation of Quetiapine Versus Conventional Escalation in Acute Schizophrenic Patients

Schizophrenia

Germany
AstraZeneca

Completed

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Bipolar Depression
AstraZeneca

Terminated

Rapid Versus Conventional Titration of Quetiapine in Schizophrenia/Schizoaffective Disorder (RAPID)

Psychotic Disorders | Schizophrenia | Schizoaffective Disorders

United Kingdom
AstraZeneca

Completed

Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (eXtRa)

Schizophrenia

Italy, Germany, Austria, Spain, Denmark
AstraZeneca

Completed

SR-Registration Study 1, ROW: Efficacy and Safety of Seroquel® in the Treatment of Patients With Schizophrenia

Schizophrenic Disorder

Bulgaria, Russian Federation, Romania, South Africa, Greece, Philippines, India, Indonesia
Pfizer

Completed

A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants

Healthy Participants

Belgium
Bayer

Completed

A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight

Renal Impairment | Chronic Kidney Disease | Healthy Volunteers

Germany
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar Disorder

United States
Alexion

Recruiting

A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants

Healthy Participants

United Kingdom
McMaster University

Completed

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Insomnia | Hot Flashes | Major Depressive Disorder

Canada
AstraZeneca

Completed

Quetiapine Fumarate as Monotherapy in the Maintenance Treatment of Patients With Major Depressive Disorder (AMETHYST)

Major Depressive Disorder

United States, Russian Federation, United Kingdom, Romania, Canada, Slovakia, Bulgaria, Puerto Rico
AstraZeneca

Withdrawn

A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects

Healthy Male Subjects | Pharmacokinetics | Safety | Food Effect

United Kingdom
AstraZeneca

Completed

Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended Release as Monotherapy in the Treatment of Patients With Bipolar Depression

Bipolar Depression

China
Ewha Womans University

Withdrawn

Effects of Seroquel XR on Sleep Architecture in Patients With Major Depressive Disorder

Major Depressive Disorder

Korea, Republic of
AstraZeneca

Completed

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

Schizophrenia

China
University of Calgary
Multiple Sclerosis Society of Canada

Completed

Safety and Tolerability of Quetiapine in Multiple Sclerosis

Multiple Sclerosis

Canada
Dr Alexander McIntyre Inc.

Completed

A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome

Major Depression

Canada
University of Regensburg
AstraZeneca

Completed

Quetiapine Induced Neuroplasticity in First-episode Schizophrenic Patients

Schizophrenia

Germany
University of Saskatchewan
AstraZeneca

Completed

Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression

Depressive Disorder, Major
AstraZeneca

Completed

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia (SPECTRUM)

Schizophrenia

Canada, Australia, Korea, Republic of, Hong Kong
Elcelyx Therapeutics, Inc.

Completed

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Type 2 Diabetes Mellitus

United States
University of Calgary
AstraZeneca

Completed

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Major Depressive Disorder

Canada
Johnson & Johnson Pharmaceutical Research & Development...
Grünenthal GmbH

Completed

Study on the Safety and Effectiveness of Switching Between Two Forms of Tapentadol in Patients With Chronic Low Back Pain

Low Back Pain
Chang Gung Memorial Hospital
AstraZeneca

Completed

Quetiapine Augmentation for Primary Anxiety Disorder or Mood Disorders With Co-morbid Anxiety Symptoms

Primary Anxiety Disorders | Mood Disorders With Comorbid Anxiety Symptoms

Taiwan
Astellas Pharma Inc

Completed

Oral Multiple-dose Study in Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Actelion

Completed

A Study of Selexipag in Healthy Male Participant

Healthy

Belgium
Astellas Pharma Inc

Completed

Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder

Major Depressive Disorder

Japan
Astellas Pharma Inc

Completed

Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers

Healthy | Plasma Concentration Change of Quetiapine

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Astellas Pharma Inc

Completed

Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder

Major Depressive Disorder Patients

Japan
Azurity Pharmaceuticals

Completed

An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users

Abuse Potential

United States
University of Minnesota
AstraZeneca; University of Iowa; Mclean Hospital

Completed

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Borderline Personality Disorder

United States
Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Quetiapine

Obesity, Morbid

Norway
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients (ESPRIT)

Schizophrenia

China
Astellas Pharma Inc

Completed

Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder

Major Depressive Disorder

Japan
Boehringer Ingelheim

Completed

A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.

HIV Infections

United States, Botswana, Germany, South Africa
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL (PET)

Depression

Sweden
Pfizer

Completed

A Study to Evaluate the Study Medication (Etrasimod) When Mixed With Food in Healthy Participants

Healthy Participants

Belgium
AstraZeneca

Completed

Fast Titration in the Treatment of Schizophrenia, Taiwan

Schizophrenia

Taiwan
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR) in Combination With an Antidepressant in the Treatment of Major Depressive Disorders (PEARL)

Major Depressive Disorder

United States
Mundipharma Research Limited

Terminated

A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR

Polymyalgia Rheumatica

United Kingdom
Dinora, Inc.
PharPoint Research, Inc.; Analgesic Solutions

Terminated

Delayed Release Prednisone in PMR

Polymyalgia Rheumatica

United States
AstraZeneca

Terminated

A Comparison of the Effectiveness of Seroquel XR and Seroquel XR Plus Lithium in Patients With Acute Bipolar Mania: An Open-label, Randomized, Parallel Groups, Rater-blinded, 4 Week, Multicenter, Comparative,Study (STAR)

Acute Bipolar Mania

Korea, Republic of
AstraZeneca

Completed

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (ANCHOR 150)

Schizophrenia | Bipolar I Disorder

United States, Russian Federation, Philippines, Malaysia, South Africa, Poland, Serbia, Ukraine, India
AstraZeneca

Completed

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia (ANCHOR 112)

Schizophrenia

United States, Russian Federation, Philippines, Malaysia, South Africa, Germany, Poland, Serbia, India, Ukraine
AstraZeneca

Completed

Quetiapine Fumarate Bipolar Maintenance Monotherapy (SPaRCLe)

Bipolar Disorder

United States, Bulgaria, Peru, Russian Federation, Philippines, Malaysia, Lithuania, Romania, Ukraine, Argentina, Taiwan, Mexico, Thailand, India, Colombia
AstraZeneca

Completed

Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania (ANCHOR 149)

Bipolar Disorder

United States
AstraZeneca

Completed

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Major Depressive Disorder (MOONSTONE)

Major Depressive Disorder

United States
Dr. Reddy's Laboratories Limited

Completed

Bioequivalence Study of Quetiapine Fumarate Tablets 300 mg Under Fasting Condition

Healthy

India
AstraZeneca

Completed

Use of Quetiapine as an Add on Therapy in the Treatment of Post Traumatic Stress Disorder

Post-Traumatic Stress Disorder

Australia

3

Subscribe